# Phase I Study of XTL6001 Injection in Healthy and Obese Subjects

> **NCT07205432** · PHASE1 · RECRUITING · sponsor: **Shanghai Xitaili Biomedicine Technology co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Weight Management in Adult Patients With Obesity or Overweight

## Interventions

- **DRUG:** XTL6001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07205432
- **Lead sponsor:** Shanghai Xitaili Biomedicine Technology co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-13
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07205432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07205432, "Phase I Study of XTL6001 Injection in Healthy and Obese Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07205432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*